查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094733

人類抗菌藥物敏感性檢測市場－全球預測（2026-2032年）

Human Antimicrobial Susceptibility Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類抗菌藥物敏感性測試市場將成長至 65 億美元，複合年成長率為 6.55%。

主要市場統計數據
基準年 2025 41.6億美元
預計年份：2026年 44.3億美元
預測年份 2032 65億美元
複合年成長率 (%) 6.55%

人類抗菌藥物敏感性試驗 (AST) 是臨床微生物學的核心功能，用於確定細菌、真菌和其他病原體對抗生素的敏感性（敏感、中度敏感或抗藥性）。隨著抗菌藥物抗藥性 (AMR) 持續威脅患者安全、手術效果、癌症治療、移植醫學、重症監護和感染控制項目，人們越來越需要更快、更標準化且臨床上適用的 AST 工作流程。世界衛生組織 (WHO) 已將 AMR 列為全球最嚴峻的公共衛生威脅之一，全球醫學證據表明，細菌 AMR 與高死亡率、更長的住院時間和更複雜的治療有關。經營團隊的重點不再局限於病原體鑑定；醫療保健系統越來越需要檢測抗藥性機制、解讀最低抑菌濃度 (MIC)、出於抗菌藥物管理目的進行報告以及與監測平台整合。人類抗菌藥物敏感性試驗 (AST) 有助於標靶治療，減少頻譜抗生素的不合理使用，並透過將檢測結果與流行病學、藥物數據和臨床結果聯繫起來，加強公共衛生監測。其實施受臨床指引、檢查室認證要求、血流感染疾病方案、敗血症管理路徑和國家抗菌藥物抗藥性行動計畫的限制。關鍵技術領域包括紙錠擴散法、肉湯微量稀釋法、自動化表現型分析系統、梯度擴散法、分子抗藥性檢測、快速抗菌藥物敏感性試驗平台、基於質譜的工作流程和數位化檢測工具。最永續的策略是將可靠的表現型確認與更快速的診斷相結合，並將其整合到合理的抗生素使用中，使臨床醫生能夠從經驗性治療轉向循證治療決策。

人類AST領域的變革性變化

在人類抗菌藥物敏感性檢測領域，一場結構性變革正在發生，從孤立的檢查室檢測轉向整合的、時間緊迫的臨床決策支援。雖然傳統的培養為基礎的抗菌藥物敏感性檢測對於評估微生物在抗生素存在下的行為仍然至關重要，但醫院越來越重視高風險感染疾病（例如敗血症、肺炎、尿道感染和醫療相關感染疾病）的快速檢測結果。自動化、快速表現型分析、分子水平抗藥性標記的鑑定以及從陽性血液培養直接進行檢測的工作流程都為這一轉變提供了支持。臨床檢查室也正在從人工審核結果轉向採用與公認基準值、品管方案和抗菌藥物使用報告要求一致的標準化解讀標準。另一個重要的轉變是抗菌藥物敏感性檢測的範圍從急性護理醫院檢查室擴展到參考實驗室、門診網路和區域監測系統。隨著對合理使用抗菌藥物的重視程度不斷提高，藥敏試驗（AST）數據正成為製定藥物清單、建立區域抗菌藥物敏感性譜、預防​​感染以及更新經驗性治療指南的重要戰略資產。另一方面，檢查室面臨著許多運作方面的限制，包括訓練有素的人員短缺、試劑標準化方面的挑戰、基準值的不斷更新、檢體運輸的限制以及需要使用參考標準檢驗新方法等。這些壓力促使人們投資於可互通的平台、整合實驗室資訊系統以及既能提供速度和準確性又不影響臨床可靠性的診斷方法。

人工智慧對人工抗菌藥物敏感性測試的累積影響。

人工智慧正透過改善影像分析、模式識別、工作流程優先排序、品管審核和預測性解讀，逐步影響人工進行的抗菌藥物敏感性試驗。在微生物檢查室中，人工智慧工具可以輔助菌落鑑定、抑菌圈直徑測量、數位平板判讀、異常檢測以及異常抗藥性表現型的自動標記。在臨床環境中，人工智慧可以將抗菌藥物敏感性試驗結果與患者病歷、腎功能、感染部位、既往抗生素暴露史、區域抗藥性模式以及抗生素合理使用指南相結合，從而幫助提案更精準的治療方案。當人工智慧作為輔助層應用時，其累積效應將最大化，它能夠促進標準化、減少重複的人工判讀並加快向臨床醫生的通知速度，同時保持專家監督和檢驗的檢測程序。人工智慧還具有累積的公共衛生意義，因為分析匯總的抗菌藥物敏感性試驗（AST）數據可以識別新出現的抗藥性叢集、檢測抗藥性趨勢的變化，並支持醫院或區域的抗菌藥物抗藥性（AMR）監測。然而，負責任的實施需要透明的檢驗、針對不同病原體群體的偏差評估、網路安全措施、可解釋的輸出、人為因素測試，以及遵守監管和臨床管治要求。在需要臨床表現型證據的情況下，人工智慧不應取代確認性藥敏試驗。相反，人工智慧可以提高處理能力、一致性和及時性，從而提供可操作的抗菌藥物抗藥性資訊。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區感染疾病負擔沉重，都市區密度高，醫院網路不斷擴張，因此抗菌藥物抗藥性（AMR）監測至關重要。因此，人類抗菌藥物敏感性檢測在臨床診療和公共衛生中發揮核心作用。儘管該地區各國都在推進檢查室能力建設，推廣抗菌藥物風險管理（IPS）項目，並擴大自動化快速診斷流程的覆蓋範圍，但先進醫療體系與資源匱乏環境之間的實施情況差異顯著。北美在標準化抗菌藥物風險管理（AST）、敗血症診療方案、自動化微生物系統、與電子健康記錄的整合以及IPS計畫方面取得了顯著進展，醫院和參考實驗室優先考慮快速報告和監測品質數據。在拉丁美洲，AMR監測正透過國家參考網路和醫院感染控制舉措推進，但檢查室基礎設施、准入限制和人員配備需求方面的差異仍然影響著AST的標準化。在歐洲，成熟的法律規範、統一的基準值解讀、跨境抗菌藥物抗藥性監測以及健全的抗菌藥物管理框架，為眾多醫療體系中抗菌藥物敏感性試驗（AST）品質的一致性提供了保障。在中東，AST正日益成為一項優先事項，尤其是在三級醫療中心和醫療旅遊中心，它被納入醫院現代化、感染預防、抗菌藥物管理和數位健康計畫之中。同時，區域差異仍然存在，這與檢查室資源和政策實施密切相關。在非洲，感染疾病負擔沉重，抗生素抗藥性日益嚴重，因此擴大AST的可近性成為當務之急。各方致力於加強診斷基礎設施、品質保證、人力資源開發、檢體遞送系統以及監測合作，以支持循證抗菌藥物的使用。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，人類抗菌藥物敏感性檢測日益融入國家抗菌藥物抗藥性（AMR）行動計劃、醫院合理用藥舉措以及區域實驗室強化項目，其重點在於能力建設、品質保證以及可靠診斷的可及性和可負擔性。海灣合作理事會（GCC）已投資於先進的醫院基礎設施、感染預防、合理使用抗菌藥物以及數位醫療系統，為在三級醫療機構引入自動化抗菌藥物敏感性檢測和快速診斷創造了有利條件。歐盟擁有統一的監測系統、循證閾值指南以及強調在人類健康領域合理使用抗菌藥物的政策，為抗菌藥物敏感性檢測標準化提供了最協調的環境之一。金磚國家（BRICS）的抗菌藥物敏感性檢測環境較為複雜，既面臨著重大感染疾病的負擔，又擁有大規模的醫院網路、不斷擴大的診斷設備生產能力以及積極的抗菌藥物耐藥性政策，但仍然面臨著區域間在可及性和檢查室質量方面的差異。七國集團（G7）國家普遍具備成熟的臨床微生物學能力、較高的合理抗生素使用率和健全的公共衛生監測體系，這使得抗菌藥物敏感性試驗（AST）數據在抗生素政策制定、醫院間基準比較和抗藥性機制研究中日益重要。北約成員國對抗菌藥物敏感性試驗具有戰略利益，因為抗菌藥物抗藥性（AMR）會影響軍事醫學、創傷救治、野戰醫院、生物防禦體係以及多國醫療保健的互通性。這進一步增加了對標準化檢測、快速病原體回應、安全資料交換以及覆蓋民用和國防醫療保健系統的穩健檢查室網路的需求。

主要國家在人體抗菌藥物敏感性測試的趨勢

在美國，已建立起高度發展的人類抗菌藥物敏感性檢測（AST）體系，該體係以臨床檢查室標準、抗菌藥物管理要求、醫院品質管理計畫和先進的感染疾病診斷技術為支撐，尤其注重血流感染疾病的快速檢測和抗菌藥物抗藥性（AMR）監測。在加拿大，標準化的檢查室操作、合理用藥以及全國範圍的抗藥性監測受到重視，各州的醫療保健系統根據自身情況制定實施方案。在墨西哥，AST能力建構正透過公共衛生監測和醫院檢查室現代化而不斷推進，但區域間服務取得的差異仍然是一項重大挑戰。在巴西，由於醫院網路大規模、感染疾病複雜以及對AMR監測的需求，AST需求量非常高，參考檢查室在標準化方面發揮著至關重要的作用。英國透過全國性的檢查室指南、抗菌藥物管理政策和監測項目，維持強大的AST管治，支持所有醫療機構的實證用藥。德國結合了先進的檢查室基礎設施、醫院感染控制計畫和可靠的診斷技術，而法國則強調合理使用抗菌藥物、監測和標準化的藥敏試驗報告。在俄羅斯，醫院和公共衛生機構對抗菌藥物敏感性試驗（AST）的需求極高，人們越來越關注醫療相關抗藥性病原體。義大利和西班牙繼續依賴AST來應對院內感染、碳青黴烯類抗藥性，並基於合理使用抗菌藥物來改進處方。中國正透過醫院現代化、監測網路建設和對快速診斷的投資來提升其AST能力，這得益於龐大的患者群體和抗菌藥物抗藥性控制的優先地位。在印度，感染疾病負擔沉重、醫療資源取得管道不均以及合理使用抗菌藥物方面面臨的巨大挑戰，使得AST的需求迫切，因此，經濟實惠、可靠且擴充性的檢測至關重要。日本的特點是擁有先進的臨床微生物學體系、嚴格的品質標準以及在醫院感染控制中積極應用AST。澳洲則受惠於系統的監測、合理用藥方案和健全的檢查室品管體系，而韓國則著重於快速診斷、醫院感染控制以及對環境中抗藥性細菌的監測，尤其關注重症患者。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠縮短臨床結果獲取時間，同時保持檢驗的表現型準確性和與公認判讀標準一致性的藥敏試驗（AST）解決方案。產品和檢查室策略應側重於以下工作流程：針對嚴重感染疾病的「直接從檢體檢測」或「直接從陽性培養物檢測」；自動化品管；與實驗室資訊系統的無縫整合；以及將藥敏試驗結果與實際處方支持聯繫起來的、符合抗生素使用習慣的彙報。決策者應投資於人才培養、斷點更新管理、檢測法檢驗、參與外部品質評估和資料管治，以確保藥敏試驗結果具有臨床可靠性，並且在不同地點之間具有可比性。與醫院、公共衛生網路和參考實驗室建立合作關係可以加強抗生素抗藥性（AMR）監測，並有助於建立區域性抗生素敏感性譜。各機構還應設計能夠滿足不同基礎架構層的解決方案，例如針對三級醫療機構的高通量自動化系統，以及針對資源受限環境的經濟高效的標準化方法。人工智慧驅動的功能應透過透明檢驗、可解釋的輸出、網路安全措施和專家審核來實現。最後，行業領導者必須使產品開發與合理使用抗菌藥物、預防感染和公共衛生報告的需求保持一致，因為抗菌藥物敏感性試驗 (AST) 的價值日益得到認可，它有助於更快地進行標靶治療、減少不合理使用抗菌藥物以及改進抗藥性監測。

調查方法

本執行摘要採用系統性的二手研究方法撰寫而成，重點關注來自臨床微生物學標準、同行檢驗文獻、公共衛生機構、抗菌藥物抗藥性監測計畫、醫院合理使用抗菌藥物指南、監管出版刊物和檢查室品管框架的已驗證且有數據支持的證據。調查方法著重探討影響人類抗菌藥物敏感性檢測的臨床相關促進因素、技術應用模式、區域政策重點和操作障礙。資訊來源包括國際公認的藥敏試驗方法和基準值解讀指南、國家抗菌藥物抗藥性行動計劃、感染疾病監測出版刊物、醫療保健品質要求以及評估藥敏試驗工作流程績效的科學研究。為避免依賴單一資料來源，本研究採用三角測量法整合了臨床、監管、公共衛生和檢查室操作等多個觀點的資訊。本調查方法不包括市場規模估算、市場佔有率估算、收入預測和供應商比較。相反，重點在於基於證據對部署趨勢、工作流程轉變、人工智慧 (AI) 的影響、區域準備情況以及與醫院、參考檢查室、公共衛生系統和合理使用計劃相關的人類抗菌藥物敏感性試驗 (AST)相關人員的戰略重點進行解釋。

結論

隨著醫療衛生系統面臨抗生素抗藥性、敗血症風險、醫療相關感染以及對更精準抗生素治療的需求等挑戰，人類抗生素敏感性試驗（AST）的戰略重要性日益凸顯。儘管該領域正朝著更快、更自動化、數位化互聯且以管理為導向的工作流程發展，但其基礎仍然是嚴格的檢查室品管、檢驗的方法和標準化的解讀。區域和國家層級的部署因醫療衛生基礎設施、監測成熟度、人才儲備和政策實施情況而異，但全球發展方向一致：AST 數據必須更快、更具互通性且更易於操作。人工智慧雖然可以提高效率和監測洞察力，但其價值取決於負責任的檢驗和專家監督。對於產業領導者而言，最大的機會在於將可靠的敏感性試驗與臨床決策支援、公共衛生報告和可擴展的部署模式相結合的解決方案。由於抗菌素抗藥性 (AMR) 持續對現代醫學構成挑戰，人類抗菌素敏感性測試 (AST) 仍將是患者照護、感染預防、合理使用抗生素和全球衛生安全的重要支柱。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人類抗菌藥物敏感性檢測市場：依產品類型分類

  • 裝置
    • 自動化AST系統
    • 半自動AST系統
    • 手動AST設備
    • 微生物分析儀
  • 消耗品
    • AST面板和卡
    • 培養基
    • 試劑和檢測試劑盒
    • 抗生素藥片
  • 軟體
    • 檢查資訊系統（LIS）整合工具
    • 人工智慧驅動的阻力評估軟體
  • 服務
    • 維護和校準服務
    • 培訓和諮詢服務

第8章：人類抗菌藥物敏感性檢測市場：依技術分類

  • 自動化系統
    • 微型掃描系統
    • 鳳凰系統
    • 維泰克系統
  • 紙錠擴散法
  • 漸變條
  • 微量稀釋法
  • 分子方法

第9章：人類抗菌藥物敏感性檢測市場：依檢測類型分類

  • 自動化檢測
  • 手動測試
    • 瓊脂稀釋法
    • 肉湯微量稀釋法
    • 紙錠擴散法
    • 漸變條

第10章：人類抗菌藥物敏感性檢測市場：依病原體分類

  • 真菌
  • 革蘭氏陰性菌
    • 腸桿菌科
    • 非腸桿菌科
  • 革蘭氏陽性菌
  • 分枝桿菌

第11章：人類抗菌藥物敏感性測試市場：按應用領域分類

  • 臨床診斷
  • 製藥
  • 研究

第12章：人類抗菌藥物敏感性測試市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 醫院
  • 研究機構

第13章：人類抗菌藥物敏感性檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：人類抗菌藥物敏感性檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：人類抗菌藥物敏感性檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Accelerate Diagnostics Inc.
  • Alifax Srl
  • Autobio Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMaxima SA
  • Bruker Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • GeneFluidics, Inc.
  • HiMedia Laboratories Pvt. Ltd.
  • iFAST Diagnostics Ltd.
  • Liofilchem Srl
  • Luminex Corporation
  • Microbiologics, Inc.
  • OpGen, Inc.
  • Prolab Incorporated
  • QIAGEN NV
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • sifin diagnostics gmbh
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific Inc.
  • Titan Biotech Limited
  • Tulip Diagnostics（P）Ltd.
  • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.50 billion at a CAGR of 6.55% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.16 billion
Estimated Year [2026] USD 4.43 billion
Forecast Year [2032] USD 6.50 billion
CAGR (%) 6.55%

Human antimicrobial susceptibility testing (AST) is a core clinical microbiology function used to determine whether bacteria, fungi, or other pathogens are susceptible, intermediate, or resistant to antimicrobial agents. As antimicrobial resistance (AMR) continues to threaten patient safety, surgical outcomes, cancer care, transplant medicine, intensive care, and infection control programs, demand is increasing for faster, standardized, and clinically actionable AST workflows. The World Health Organization recognizes AMR as one of the top global public health threats, and global health evidence links bacterial AMR to substantial mortality, longer hospital stays, and higher treatment complexity. The executive priority is no longer limited to identifying an organism; healthcare systems increasingly need resistance mechanism detection, minimum inhibitory concentration interpretation, stewardship-ready reporting, and connectivity to surveillance platforms. Human AST supports targeted therapy, reduces inappropriate broad-spectrum antimicrobial use, and strengthens public health monitoring by linking laboratory results with epidemiology, pharmacy data, and clinical outcomes. Adoption is being shaped by clinical guidelines, laboratory accreditation requirements, bloodstream infection protocols, sepsis management pathways, and national AMR action plans. Key technology areas include disk diffusion, broth microdilution, automated phenotypic systems, gradient diffusion, molecular resistance testing, rapid AST platforms, mass spectrometry-enabled workflows, and digital interpretation tools. The most resilient strategies combine reliable phenotypic confirmation with faster diagnostics and antimicrobial stewardship integration, enabling clinicians to move from empiric therapy toward evidence-based treatment decisions.

Transformative Shifts in the Human AST Landscape

The human antimicrobial susceptibility testing landscape is undergoing a structural shift from isolated laboratory testing toward integrated, time-sensitive clinical decision support. Traditional culture-based AST remains essential because it measures organism behavior in the presence of antimicrobial agents, but hospitals are increasingly prioritizing shorter turnaround times for high-risk infections such as sepsis, pneumonia, urinary tract infections, and healthcare-associated infections. This shift is supported by automation, rapid phenotypic testing, molecular resistance marker identification, and direct-from-positive-blood-culture workflows. Clinical laboratories are also moving from manual result review toward standardized interpretive criteria aligned with recognized breakpoints, quality control protocols, and stewardship reporting needs. Another important transformation is the expansion of AST beyond acute hospital laboratories into reference laboratories, outpatient networks, and regional surveillance systems. Growing emphasis on antimicrobial stewardship has made AST data a strategic asset for formulary decisions, local antibiogram development, infection prevention, and empiric therapy guideline updates. At the same time, laboratories face operational constraints, including trained workforce shortages, reagent standardization challenges, evolving breakpoint updates, specimen transport limitations, and the need to validate new methods against reference standards. These pressures are encouraging investment in interoperable platforms, laboratory information system integration, and diagnostics that deliver both speed and confidence without compromising clinical reliability.

Cumulative Impact of Artificial Intelligence on Human AST

Artificial intelligence is beginning to influence human antimicrobial susceptibility testing by improving image analysis, pattern recognition, workflow prioritization, quality control review, and predictive interpretation. In microbiology laboratories, AI-enabled tools can support colony recognition, zone diameter reading, digital plate interpretation, anomaly detection, and automated flagging of unusual resistance phenotypes. In clinical settings, AI can help combine AST results with patient history, renal function, infection site, prior antibiotic exposure, local resistance patterns, and stewardship rules to support more precise therapy recommendations. The cumulative impact is greatest when AI is implemented as an assistive layer that enhances standardization, reduces repetitive manual interpretation, and accelerates clinician notification, while maintaining expert oversight and validated laboratory procedures. AI also has public health relevance because aggregated AST data can be analyzed to identify emerging resistance clusters, detect changes in resistance trends, and support hospital-level or regional AMR surveillance. However, responsible adoption requires transparent validation, bias assessment across diverse pathogen populations, cybersecurity controls, explainable outputs, human factors testing, and alignment with regulatory and clinical governance requirements. AI should not replace confirmatory susceptibility testing where phenotypic evidence is clinically required; rather, it can improve throughput, consistency, and the timeliness of actionable antimicrobial resistance insights.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific is characterized by high infectious disease burden, dense urban populations, expanding hospital networks, and significant AMR surveillance priorities, making human antimicrobial susceptibility testing central to clinical care and public health. Countries across the region are strengthening laboratory capacity, promoting stewardship programs, and expanding access to automated and rapid diagnostic workflows, although adoption varies widely between advanced healthcare systems and resource-constrained settings. North America demonstrates strong uptake of standardized AST, sepsis protocols, automated microbiology systems, electronic medical record integration, and antimicrobial stewardship programs, with hospitals and reference laboratories emphasizing rapid reporting and surveillance-quality data. Latin America is advancing AMR monitoring through national reference networks and hospital infection-control initiatives, but laboratory infrastructure differences, access constraints, and workforce needs continue to influence AST standardization. Europe benefits from mature regulatory oversight, harmonized breakpoint interpretation, cross-border AMR monitoring, and strong stewardship frameworks, supporting consistent AST quality across many healthcare systems. The Middle East is increasingly prioritizing AST as part of hospital modernization, infection prevention, antimicrobial stewardship, and digital health programs, particularly in tertiary care and medical tourism hubs, while regional variation remains linked to laboratory resources and policy implementation. Africa faces some of the most urgent needs for expanded AST access due to infectious disease burden and rising resistance, with progress focused on strengthening diagnostic infrastructure, quality assurance, workforce training, specimen referral systems, and surveillance connectivity to support evidence-based antimicrobial use.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are increasingly aligning human antimicrobial susceptibility testing with national AMR action plans, hospital stewardship initiatives, and regional laboratory-strengthening programs, with priorities centered on capacity building, quality assurance, and affordable access to reliable diagnostics. The GCC is investing in advanced hospital infrastructure, infection prevention, antimicrobial stewardship, and digital health systems, creating favorable conditions for automated AST and rapid diagnostic adoption in tertiary care environments. The European Union provides one of the most coordinated environments for AST standardization, supported by harmonized surveillance systems, evidence-based breakpoint guidance, and policy emphasis on responsible antimicrobial use across human health. BRICS countries represent a diverse AST environment, combining major infectious disease burdens, large hospital networks, growing diagnostic manufacturing capacity, and active AMR policy development, while still facing uneven access and laboratory quality variation across regions. G7 countries generally demonstrate mature clinical microbiology capacity, high stewardship penetration, and strong public health surveillance, making AST data increasingly important for antimicrobial policy, hospital benchmarking, and research into resistance mechanisms. NATO member countries have a strategic interest in AST because AMR affects military medicine, trauma care, field hospitals, biodefense readiness, and multinational healthcare interoperability; this reinforces the need for standardized testing, rapid pathogen response, secure data exchange, and resilient laboratory networks across civilian and defense health systems.

Key Country Insights in Human Antimicrobial Susceptibility Testing

The United States has a highly developed human AST ecosystem supported by clinical laboratory standards, antimicrobial stewardship requirements, hospital quality programs, and advanced infectious disease diagnostics, with strong focus on rapid bloodstream infection testing and AMR surveillance. Canada emphasizes standardized laboratory practices, stewardship integration, and national resistance monitoring, with provincial healthcare structures shaping implementation. Mexico is strengthening AST capacity through public health surveillance and hospital laboratory modernization, while access variability remains important across regions. Brazil has substantial AST demand due to large hospital networks, infectious disease complexity, and AMR monitoring needs, with reference laboratories playing an important role in standardization. The United Kingdom maintains strong AST governance through national laboratory guidance, stewardship policies, and surveillance programs, supporting evidence-based prescribing across healthcare settings. Germany combines advanced laboratory infrastructure, hospital infection-control programs, and robust diagnostic adoption, while France emphasizes stewardship, surveillance, and standardized susceptibility reporting. Russia has significant need for AST across hospital and public health settings, with growing attention to resistant healthcare-associated pathogens. Italy and Spain continue to rely on AST to address hospital-acquired infections, carbapenem-resistant organisms, and stewardship-driven prescribing improvements. China is expanding AST capacity through hospital modernization, surveillance networks, and investment in rapid diagnostics, driven by large patient volumes and AMR containment priorities. India has urgent AST needs due to high infectious disease burden, diverse healthcare access, and major antimicrobial stewardship challenges, making affordable, reliable, and scalable testing critical. Japan has advanced clinical microbiology systems, strict quality expectations, and strong use of AST in hospital infection management. Australia benefits from structured surveillance, stewardship programs, and strong laboratory quality systems, while South Korea emphasizes rapid diagnostics, hospital infection control, and monitoring of resistant organisms in high-acuity settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AST solutions that improve clinical turnaround time while preserving validated phenotypic accuracy and alignment with recognized interpretive standards. Product and laboratory strategies should focus on direct-from-sample or direct-from-positive-culture workflows for critical infections, automated quality control, seamless laboratory information system integration, and stewardship-ready reporting that translates susceptibility results into practical prescribing support. Decision-makers should invest in workforce training, breakpoint update management, method verification, external quality assessment participation, and data governance to ensure AST results remain clinically reliable and comparable across sites. Partnerships with hospitals, public health networks, and reference laboratories can strengthen AMR surveillance and support local antibiogram development. Organizations should also design solutions for varied infrastructure levels, including high-throughput automated systems for tertiary hospitals and cost-effective standardized methods for resource-limited settings. AI-enabled features should be deployed with transparent validation, explainable outputs, cybersecurity safeguards, and human expert review. Finally, industry leaders should align product development with antimicrobial stewardship, infection prevention, and public health reporting needs, because the value of AST is increasingly measured by its contribution to faster targeted therapy, reduced inappropriate antimicrobial use, and improved resistance monitoring.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, data-backed evidence from clinical microbiology standards, peer-reviewed literature, public health agencies, AMR surveillance programs, hospital stewardship guidance, regulatory publications, and laboratory quality frameworks. The analysis emphasizes clinically relevant drivers, technology adoption patterns, regional policy priorities, and operational barriers affecting human antimicrobial susceptibility testing. Sources considered include internationally recognized guidance on susceptibility testing methods and breakpoint interpretation, national AMR action plans, infectious disease surveillance publications, healthcare quality requirements, and scientific studies evaluating AST workflow performance. Insights were synthesized using triangulation across clinical, regulatory, public health, and laboratory operations perspectives to avoid reliance on a single data source. The methodology excludes market sizing, market share estimation, revenue forecasting, and vendor comparison. Instead, it focuses on evidence-based interpretation of adoption trends, workflow transformation, artificial intelligence implications, regional readiness, and strategic priorities for stakeholders involved in human AST across hospitals, reference laboratories, public health systems, and stewardship programs.

Conclusion

Human antimicrobial susceptibility testing is becoming increasingly strategic as healthcare systems confront antimicrobial resistance, sepsis risk, healthcare-associated infections, and the need for more precise antimicrobial therapy. The field is moving toward faster, more automated, digitally connected, and stewardship-oriented workflows, but the foundation remains rigorous laboratory quality, validated testing methods, and standardized interpretation. Regional and country-level adoption differs according to healthcare infrastructure, surveillance maturity, workforce availability, and policy execution, yet the global direction is consistent: AST data must become faster, more interoperable, and more actionable. Artificial intelligence can enhance efficiency and surveillance intelligence, but its value depends on responsible validation and expert oversight. For industry leaders, the strongest opportunities lie in solutions that connect reliable susceptibility testing with clinical decision support, public health reporting, and scalable implementation models. As AMR continues to challenge modern medicine, human AST will remain a critical pillar of patient care, infection prevention, antimicrobial stewardship, and global health security.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Antimicrobial Susceptibility Testing Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
    • 7.2.1. Automated AST Systems
    • 7.2.2. Semi-Automated AST Systems
    • 7.2.3. Manual AST Instruments
    • 7.2.4. Microbiology Analyzers
  • 7.3. Consumables
    • 7.3.1. AST Panels & Cards
    • 7.3.2. Culture Media
    • 7.3.3. Reagents & Assay Kits
    • 7.3.4. Antibiotic Discs
  • 7.4. Software
    • 7.4.1. Laboratory Information System (LIS) Integration Tools
    • 7.4.2. AI-Based Resistance Interpretation Software
  • 7.5. Services
    • 7.5.1. Maintenance & Calibration Services
    • 7.5.2. Training & Consulting Services

8. Human Antimicrobial Susceptibility Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Automated Systems
    • 8.2.1. MicroScan Systems
    • 8.2.2. Phoenix Systems
    • 8.2.3. Vitek Systems
  • 8.3. Disk Diffusion
  • 8.4. Gradient Strip
  • 8.5. Microdilution
  • 8.6. Molecular Methods

9. Human Antimicrobial Susceptibility Testing Market, by Test Type

  • 9.1. Introduction
  • 9.2. Automated Testing
  • 9.3. Manual Testing
    • 9.3.1. Agar Dilution
    • 9.3.2. Broth Microdilution
    • 9.3.3. Disk Diffusion
    • 9.3.4. Gradient Strip

10. Human Antimicrobial Susceptibility Testing Market, by Pathogen

  • 10.1. Introduction
  • 10.2. Fungi
  • 10.3. Gram Negative Bacteria
    • 10.3.1. Enterobacteriaceae
    • 10.3.2. Non Enterobacteriaceae
  • 10.4. Gram Positive Bacteria
  • 10.5. Mycobacteria

11. Human Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Introduction
  • 11.2. Clinical Diagnostics
  • 11.3. Pharmaceutical
  • 11.4. Research

12. Human Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals
  • 12.5. Research Institutes

13. Human Antimicrobial Susceptibility Testing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Human Antimicrobial Susceptibility Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Human Antimicrobial Susceptibility Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Accelerate Diagnostics Inc.
  • 17.2. Alifax S.r.l.
  • 17.3. Autobio Diagnostics Co., Ltd.
  • 17.4. Becton, Dickinson and Company
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. BioMaxima S.A.
  • 17.7. Bruker Corporation
  • 17.8. Danaher Corporation
  • 17.9. F. Hoffmann-La Roche AG
  • 17.10. GeneFluidics, Inc.
  • 17.11. HiMedia Laboratories Pvt. Ltd.
  • 17.12. iFAST Diagnostics Ltd.
  • 17.13. Liofilchem S.r.l.
  • 17.14. Luminex Corporation
  • 17.15. Microbiologics, Inc.
  • 17.16. OpGen, Inc.
  • 17.17. Prolab Incorporated
  • 17.18. QIAGEN N.V.
  • 17.19. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 17.20. Shimadzu Corporation
  • 17.21. Siemens Healthineers AG
  • 17.22. sifin diagnostics gmbh
  • 17.23. T2 Biosystems, Inc.
  • 17.24. Thermo Fisher Scientific Inc.
  • 17.25. Titan Biotech Limited
  • 17.26. Tulip Diagnostics (P) Ltd.
  • 17.27. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED AST SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED AST SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED AST SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEMI-AUTOMATED AST SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEMI-AUTOMATED AST SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEMI-AUTOMATED AST SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MANUAL AST INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MANUAL AST INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MANUAL AST INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOLOGY ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOLOGY ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOLOGY ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AST PANELS & CARDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AST PANELS & CARDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AST PANELS & CARDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL REAGENTS & ASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL REAGENTS & ASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL REAGENTS & ASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC DISCS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC DISCS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC DISCS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LABORATORY INFORMATION SYSTEM (LIS) INTEGRATION TOOLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LABORATORY INFORMATION SYSTEM (LIS) INTEGRATION TOOLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LABORATORY INFORMATION SYSTEM (LIS) INTEGRATION TOOLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AI-BASED RESISTANCE INTERPRETATION SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AI-BASED RESISTANCE INTERPRETATION SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AI-BASED RESISTANCE INTERPRETATION SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAINTENANCE & CALIBRATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAINTENANCE & CALIBRATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MAINTENANCE & CALIBRATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRAINING & CONSULTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRAINING & CONSULTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRAINING & CONSULTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICROSCAN SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICROSCAN SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICROSCAN SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHOENIX SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHOENIX SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHOENIX SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VITEK SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VITEK SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VITEK SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DISK DIFFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DISK DIFFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DISK DIFFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GRADIENT STRIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GRADIENT STRIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GRADIENT STRIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICRODILUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MICRODILUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MICRODILUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MANUAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MANUAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MANUAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AGAR DILUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AGAR DILUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AGAR DILUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BROTH MICRODILUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BROTH MICRODILUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BROTH MICRODILUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DISK DIFFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DISK DIFFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DISK DIFFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GRADIENT STRIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GRADIENT STRIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GRADIENT STRIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FUNGI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FUNGI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FUNGI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GRAM NEGATIVE BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GRAM NEGATIVE BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GRAM NEGATIVE BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NON ENTEROBACTERIACEAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON ENTEROBACTERIACEAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON ENTEROBACTERIACEAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GRAM POSITIVE BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GRAM POSITIVE BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GRAM POSITIVE BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MYCOBACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MYCOBACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MYCOBACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 249. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 250. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 290. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 291. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 292. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 298. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 300. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 304. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 305. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 306. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING M